A Phase 1 interventional study of Omecamtiv Mecarbil (OM) and Placebo in QT Intervals Changes and QTc Intervals Changes, sponsored by Cytokinetics. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-30.
Sponsored by Cytokinetics · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to assess the effect of a single therapeutic (50 mg) oral dose of omecamtiv mecarbil (OM) on the QT interval / QT interval corrected for heart rate (QTc), relative to placebo, in healthy adults.
The QT interval is the section on an electrocardiogram (ECG) that represents the time it takes for the electrical system to fire an impulse through the ventricles and then recharge, or the time it takes for the heart muscle to contract and then recover.
The study consists of 2 parts: Part A and Part B. Participants are enrolled in Part A to determine eligibility for Part B.
In Part A participants receive a single oral dose of 25 mg omecamtiv mecarbil; participants with a resulting maximum observed OM plasma concentration (Cmax) ≤ 350 ng/mL are eligible to enter Part B.
Part B is a 3-period cross-over study in which participants are randomized to receive 3 treatments in 1 of 6 sequences, each separated by a washout of at least 7 days.
This study was conducted by Amgen as the IND holder, with Cytokinetics as a collaborator. Due to the termination of the collaboration agreement between Amgen and Cytokinetics in May 2021 and subsequent transfer of the omecamtiv mecarbil IND from Amgen to Cytokinetics, Cytokinetics is now listed as the sponsor.
Cytokinetics is the lead sponsor of 41 studies on the registry; 3 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 7 (64%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
After an overnight fast of at least 10 hours participants received a single oral dose of 25 mg omecamtiv mecarbil on Day 1.
Drug: Omecamtiv Mecarbil (OM)
Participants with a maximum observed plasma OM concentration ≤ 350 ng/mL in Part A were randomly assigned to receive a single dose of each the following 3 treatments in one of six treatment sequences: * Placebo * 50 mg omecamtiv mecarbil * 400 mg moxifloxacin Each treatment was separated by a washout of at least 7 days.
Drug: Omecamtiv Mecarbil (OM) · Drug: Placebo · Drug: Moxifloxacin
Oral solution
Also known as: AMG 423
Placebo oral solution
400 mg moxifloxacin oral tablet
Placebo-corrected Change From Baseline in QT Interval Corrected for Heart Rate Based on the Fridericia Method (QTcF) After Omecamtiv Mecarbil Dosing in Part B
Continuous 12-lead digital ECG recording was performed on day 1 of each period. ECGs were analyzed by a blinded, central reader. At each specified timepoint, ten 14-second 12-lead ECG tracings were extracted from the continuous recordings. The median QT in each replicate was calculated; the mean of available medians was used as the participant's reportable value at that timepoint. QT interval was corrected for heart rate using Fridericia's correction (QTcF). Change from baseline (ΔQTcF) was calculated based on a linear mixed-effects model with period, sequence, time (categorical), treatment, and time-by-treatment interaction as fixed effects and baseline QTcF as covariate. Placebo-corrected ΔQTcF (ΔΔQTcF) was calculated as the adjusted mean ΔQTcF after OM dosing minus adjusted mean ΔQTcF after placebo. If the upper bound of the confidence interval of ΔΔQTcF was \< 10 ms for all post-dose time points, OM was to be concluded to not have a significant effect on QT interval prolongation.
Time frame: Baseline (average of samples taken at -1.25, -1, and -0.75 hours predose on day 1 of the treatment period) and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12, and 24 hours post-dose
Maximum Observed Plasma Concentration (Cmax) of Omecamtiv Mecarbil in Part B
Plasma samples at each timepoint were quantified using a validated liquid chromatography-tandem mass spectrometry method. The lower limit of quantification for plasma samples was 1 ng/mL.
Time frame: Day 1 of the OM treatment period at pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12, 24, 48, 72, 96, and 120 hours post-dose.
Time to Maximum Observed Plasma Concentration (Tmax) of Omecamtiv Mecarbil In Part B
Time frame: Day 1 of the OM treatment period at pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12, 24, 48, 72, 96, and 120 hours post-dose.
Apparent Terminal Elimination Half-life (T1/2) of Omecamtiv Mecarbil in Part B
Time frame: Day 1 of the OM treatment period at pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12, 24, 48, 72, 96, and 120 hours post-dose.
Apparent Total Plasma Clearance (CL/F) for Omecamtiv Mecarbil in Part B
Time frame: Day 1 of the OM treatment period at pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12, 24, 48, 72, 96, and 120 hours post-dose.
Apparent Volume of Distribution (VZ/F) for Omecamtiv Mecarbil in Part B
Time frame: Day 1 of the OM treatment period at pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12, 24, 48, 72, 96, and 120 hours post-dose.
Area Under the Concentration-time Curve From Time 0 to the Time of Last Quantifiable Concentration (AUC0-t) for Omecamtiv Mecarbil in Part B
Time frame: Day 1 of the OM treatment period at pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12, 24, 48, 72, 96, and 120 hours post-dose.
AUC From Time 0 to Infinity (AUCinf) for Omecamtiv Mecarbil in Part B
Time frame: Day 1 of the OM treatment period at pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12, 24, 48, 72, 96, and 120 hours post-dose.
Placebo-corrected Change From Baseline in QT Interval Corrected for Heart Rate Based on the Fridericia Method (QTcF) After Moxifloxacin Dosing in Part B
Assay sensitivity was validated by analysis of ∆QTcF of moxifloxacin. Continuous 12-lead digital ECG recording was performed on Day 1 of each period. ECGs were analyzed by a blinded, central reader. At each specified timepoint, ten 14-second 12-lead ECG tracings were extracted from the continuous recordings. The median QT in each replicate was calculated; the mean of available medians was used as the participant's reportable value at that timepoint. QT interval was corrected for heart rate using Fridericia's correction (QTcF). Change from baseline (ΔQTcF) was calculated based on a linear mixed-effects model with period, sequence, time (categorical), treatment, and time-by-treatment interaction as fixed effects and baseline QTcF as covariate. Placebo-corrected ΔQTcF (ΔΔQTcF) was calculated as the adjusted mean ΔQTcF after moxifloxacin dosing minus adjusted mean ΔQTcF after placebo. If ∆∆QTcF was larger than 5 ms at 2, 3, or 4 hours, assay sensitivity was considered to be demonstrated.
Time frame: Baseline (average of samples taken at -1.25, -1, and -0.75 hours predose on day 1 of the moxifloxacin treatment period) and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12, and 24 hours post-dose.
Change From Baseline in Heart Rate After Omecamtiv Mecarbil Dosing in Part B
Change from baseline in heart rate (HR) was calculated based on a linear mixed-effects model with period, sequence, time (categorical), treatment, and time-by-treatment interaction as fixed effects and baseline HR as a covariate.
Time frame: Baseline (average of samples taken at -1.25, -1, and -0.75 hours predose on day 1 of the OM treatment period) and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12, and 24 hours post-dose.
Change From Baseline in QTcF After Omecamtiv Mecarbil Dosing in Part B
Change from baseline in QTcF was calculated based on a linear mixed-effects model with period, sequence, time (categorical), treatment, and time-by-treatment interaction as fixed effects and baseline QTcF as a covariate.
Time frame: Baseline (average of samples taken at -1.25, -1, and -0.75 hours predose on day 1 of the OM treatment period) and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12, and 24 hours post-dose.
Change From Baseline in PR Interval After Omecamtiv Mecarbil Dosing in Part B
The PR interval is the time from the onset of the P-wave to the start of the next QRS complex. Change from baseline was calculated based on a linear mixed-effects model with period, sequence, time (categorical), treatment, and time-by-treatment interaction as fixed effects and baseline PR interval as covariate.
Time frame: Baseline (average of samples taken at -1.25, -1, and -0.75 hours predose on day 1 of the OM treatment period) and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12, and 24 hours post-dose.
Change From Baseline in QRS After Omecamtiv Mecarbil Dosing in Part B
The QRS complex is a combination of the Q wave, R wave and S wave on an ECG tracing, and represents ventricular depolarization. Change from baseline was calculated based on a linear mixed-effects model with period, sequence, time (categorical), treatment, and time-by-treatment interaction as fixed effects and baseline QRS as covariate.
Time frame: Baseline (average of samples taken at -1.25, -1, and -0.75 hours predose on day 1 of the OM treatment period) and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12, and 24 hours post-dose.
Slope of Omecamtiv Mecarbil Plasma Concentration Estimated From Concentration-QTc Analysis in Part B
The relationship between omecamtiv mecarbil plasma concentration and ΔQTcF was investigated by linear mixed-effects modeling with ΔQTcF as the dependent variable, time-matched concentration of OM as the explanatory variable (0 for placebo), centered baseline QTcF (i.e., baseline QTcF for individual subject minus the population mean baseline QTcF for all subjects in the same period) as an additional covariate, study treatment (OM = 1 or placebo = 0) and time (i.e., post-dose time point) as fixed effects, and a random intercept and slope per subject. From the model, the slope (i.e., the regression parameter for the concentration) was estimated together with the 2-sided 90% CI.
Time frame: Baseline (average of samples taken at -1.25, -1, and -0.75 hours predose on day 1 of the OM treatment period) and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12, and 24 hours post-dose.
Placebo-corrected Change From Baseline in Heart Rate After Omecamtiv Mecarbil Dosing in Part B
Change from baseline in heart rate (ΔHR) was calculated based on a linear mixed-effects model with period, sequence, time (categorical), treatment, and time-by-treatment interaction as fixed effects and baseline HR as covariate. Placebo-corrected ΔHR (ΔΔHR) was calculated as the adjusted mean ΔHR after OM dosing minus adjusted mean ΔHR after placebo dosing.
Time frame: Baseline (average of samples taken at -1.25, -1, and -0.75 hours predose on day 1 of the OM treatment period) and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12, and 24 hours post-dose.
Placebo-corrected Change From Baseline in PR Interval After Omecamtiv Mecarbil Dosing in Part B
Change from baseline in PR interval (ΔPR) was calculated based on a linear mixed-effects model with period, sequence, time (categorical), treatment, and time-by-treatment interaction as fixed effects and baseline PR interval as covariate. Placebo-corrected ΔPR (ΔΔPR) was calculated as the adjusted mean ΔPR after OM dosing minus adjusted mean ΔPR after placebo dosing.
Time frame: Baseline (average of samples taken at -1.25, -1, and -0.75 hours predose on day 1 of the OM treatment period) and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12, and 24 hours post-dose.
Placebo-corrected Change From Baseline in QRS After Omecamtiv Mecarbil Dosing in Part B
Change from baseline in QRS (ΔQRS) was calculated based on a linear mixed-effects model with period, sequence, time (categorical), treatment, and time-by-treatment interaction as fixed effects and baseline QRS as covariate. Placebo-corrected ΔQRS (ΔΔQRS) was calculated as the adjusted mean ΔQRS after OM dosing minus adjusted mean ΔQRS after placebo dosing.
Time frame: Baseline (average of samples taken at -1.25, -1, and -0.75 hours predose on day 1 of the OM treatment period) and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12, and 24 hours post-dose.
Number of Participants With Recorded Outlier Values for QTcF, HR, PR, and QRS After Omecamtiv Mecarbil Dosing in Part B
Outliers were predefined according to the following categories: QTcF: Treatment-emergent value of \> 450 and ≤ 480 ms when not present at baseline (new onset) Treatment-emergent value of \> 480 and ≤ 500 ms when not present at baseline (new onset) Treatment-emergent value of \> 500 ms when not present at baseline (new onset) Increase of QTcF from baseline of \> 30 and ≤ 60 ms Increase of QTcF from baseline \> 60 ms Increase of PR from baseline \> 25% resulting in PR \> 200 ms Increase of QRS from baseline \> 25% resulting in QRS \> 120 ms Decrease of HR from baseline \> 25% resulting in HR \< 50 bpm Increase of HR from baseline \> 25% resulting in HR \> 100 bpm
Time frame: Day 1 of the OM treatment period at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12, and 24 hours post-dose.
Number of Participants With Treatment-emergent Changes in T-wave Morphology and U-wave Presence After Omecamtiv Mecarbil Dosing in Part B
T-wave abnormalities were categorized as follows: Flat T-wave: T amplitude \< 1 mm (either positive or negative) including flat isoelectric line Notched T-wave (+): Presence of notch(es) of at least 0.05 mV amplitude on ascending or descending arm of the positive T-wave Biphasic: T-wave that contains a second component with an opposite phase that is at least 0.1 mV deep (both positive/negative and negative/positive and polyphasic T-waves included) Normal T-wave (-): T amplitude that is negative, without biphasic T-wave or notches Notched T-wave (-): Presence of notch(es) of at least 0.05 mV amplitude on descending or ascending arm of the negative T-wave U waves: Presence of abnormal U-waves
Time frame: Day 1 of the OM treatment period at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12, and 24 hours post-dose.
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
A TEAE was defined as an adverse event (AE) that started during or after the first dose, or started prior to the first dose and increased in severity after the first dose. A treatment-related TEAE was defined as a TEAE with a relationship of related to the study treatment as determined by the investigator. The Investigator assessed the severity of each AE reported during the study based on the following grading scale: Mild: Aware of sign or symptom, easily tolerated Moderate: Discomfort enough to cause interference with usual activity Severe: Incapacitating, inability to work or do usual activity SAEs were defined as any untoward medical occurrence that met at least 1 of the following serious criteria: * Resulted in Death * Was life-threatening * Required in-patient hospitalization or prolongation of existing hospitalization * Resulted in persistent or significant disability/incapacity * Was a congenital anomaly/birth defect * Other medically important serious event
Time frame: From first dose of study treatment to day 6 of each treatment period
Number of Participants With Clinically Significant Abnormalities in Vital Signs, Laboratory Tests, or Electrocardiogram Findings
Blood and urine samples were collected for clinical laboratory evaluations (including clinical chemistry, hematology, urinalysis, and serology). Vital signs included blood pressure, pulse rate and body temperature. Standard safety 12-lead ECGs were recorded after the subject had been supine or semi-recumbent and at rest for at least 5 minutes to detect any immediate ECG effects for subject safety. These ECGs were viewed locally. The Investigator determined whether an abnormal value in an individual participant represented a clinically significant change from the participant's baseline values.
Time frame: From first dose up to day 6 of each treatment period
Participants were enrolled at a single site in the United Kingdom. The study consisted of 2 parts: Part A and Part B. Part A was a lead-in phase to ensure that omecamtiv mecarbil (OM) plasma concentrations in Part B would not exceed 1000 ng/mL.
| Milestone | Part A | Part B: Placebo/OM/Moxifloxacin | Part B: OM/Moxifloxacin/Placebo | Part B: Moxifloxacin/Placebo/OM | Part B: Placebo/Moxifloxacin/OM | Part B: Moxifloxacin/OM/Placebo | Part B: OM/Placebo/Moxifloxacin |
|---|---|---|---|---|---|---|---|
| Started | 70 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 68 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Miscellaneous | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A | Part B: Placebo/OM/Moxifloxacin | Part B: OM/Moxifloxacin/Placebo | Part B: Moxifloxacin/Placebo/OM | Part B: Placebo/Moxifloxacin/OM | Part B: Moxifloxacin/OM/Placebo | Part B: OM/Placebo/Moxifloxacin |
|---|---|---|---|---|---|---|---|
| Started | 0 | 10 | 10 | 10 | 10 | 10 | 10 |
| Completed | 0 | 10 | 10 | 10 | 10 | 10 | 10 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Continuous 12-lead digital ECG recording was performed on day 1 of each period. ECGs were analyzed by a blinded, central reader. At each specified timepoint, ten 14-second 12-lead ECG tracings were extracted from the continuous recordings. The median QT in each replicate was calculated; the mean of available medians was used as the participant's reportable value at that timepoint. QT interval was corrected for heart rate using Fridericia's correction (QTcF). Change from baseline (ΔQTcF) was calculated based on a linear mixed-effects model with period, sequence, time (categorical), treatment, and time-by-treatment interaction as fixed effects and baseline QTcF as covariate. Placebo-corrected ΔQTcF (ΔΔQTcF) was calculated as the adjusted mean ΔQTcF after OM dosing minus adjusted mean ΔQTcF after placebo. If the upper bound of the confidence interval of ΔΔQTcF was \< 10 ms for all post-dose time points, OM was to be concluded to not have a significant effect on QT interval prolongation.
| ms | Part B: Omecamtiv Mecarbil 50 mg |
|---|---|
| 0.25 hours post-dose | -2.6 (-3.87 to -1.24) |
| 0.5 hours post-dose | -4.9 (-6.40 to -3.45) |
| 0.75 hours post-dose | -5.8 (-7.34 to -4.18) |
| 1 hour post-dose | -6.7 (-8.13 to -5.29) |
| 1.5 hours post-dose | -4.5 (-5.95 to -2.98) |
| 2 hours post-dose | -2.7 (-4.21 to -1.18) |
| 3 hours post-dose | -1.5 (-2.96 to -0.10) |
| 4 hours post-dose | -0.8 (-2.35 to 0.70) |
| 8 hours post-dose | -2.2 (-4.10 to -0.24) |
| 12 hours post-dose | -1.9 (-3.98 to 0.22) |
| 24 hours post-dose | -1.2 (-2.68 to 0.30) |
Plasma samples at each timepoint were quantified using a validated liquid chromatography-tandem mass spectrometry method. The lower limit of quantification for plasma samples was 1 ng/mL.
| ng/mL | Part B: Omecamtiv Mecarbil 50 mg |
|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Omecamtiv Mecarbil in Part B | 416 ± 33.2 |
| hours | Part B: Omecamtiv Mecarbil 50 mg |
|---|---|
| Time to Maximum Observed Plasma Concentration (Tmax) of Omecamtiv Mecarbil In Part B | 0.583 (0.333 to 1.08) |
| hours | Part B: Omecamtiv Mecarbil 50 mg |
|---|---|
| Apparent Terminal Elimination Half-life (T1/2) of Omecamtiv Mecarbil in Part B | 20.0 ± 2.91 |
| L/h | Part B: Omecamtiv Mecarbil 50 mg |
|---|---|
| Apparent Total Plasma Clearance (CL/F) for Omecamtiv Mecarbil in Part B | 10.4 ± 21.2 |
| liters | Part B: Omecamtiv Mecarbil 50 mg |
|---|---|
| Apparent Volume of Distribution (VZ/F) for Omecamtiv Mecarbil in Part B | 299 ± 21.5 |
| h*ng/mL | Part B: Omecamtiv Mecarbil 50 mg |
|---|---|
| Area Under the Concentration-time Curve From Time 0 to the Time of Last Quantifiable Concentration (AUC0-t) for Omecamtiv Mecarbil in Part B | 4710 ± 21.0 |
| h*ng/mL | Part B: Omecamtiv Mecarbil 50 mg |
|---|---|
| AUC From Time 0 to Infinity (AUCinf) for Omecamtiv Mecarbil in Part B | 4790 ± 21.2 |
Assay sensitivity was validated by analysis of ∆QTcF of moxifloxacin. Continuous 12-lead digital ECG recording was performed on Day 1 of each period. ECGs were analyzed by a blinded, central reader. At each specified timepoint, ten 14-second 12-lead ECG tracings were extracted from the continuous recordings. The median QT in each replicate was calculated; the mean of available medians was used as the participant's reportable value at that timepoint. QT interval was corrected for heart rate using Fridericia's correction (QTcF). Change from baseline (ΔQTcF) was calculated based on a linear mixed-effects model with period, sequence, time (categorical), treatment, and time-by-treatment interaction as fixed effects and baseline QTcF as covariate. Placebo-corrected ΔQTcF (ΔΔQTcF) was calculated as the adjusted mean ΔQTcF after moxifloxacin dosing minus adjusted mean ΔQTcF after placebo. If ∆∆QTcF was larger than 5 ms at 2, 3, or 4 hours, assay sensitivity was considered to be demonstrated.
| ms | Part B: Moxifloxacin 400 mg |
|---|---|
| 0.25 hours post-dose | 2.2 (0.89 to 3.53) |
| 0.5 hours post-dose | 8.6 (7.11 to 10.05) |
| 0.75 hours post-dose | 10.1 (8.51 to 11.67) |
| 1 hour post-dose | 10.2 (8.74 to 11.58) |
| 1.5 hours post-dose | 11.1 (9.61 to 12.59) |
| 2 hours post-dose | 12.7 (11.13 to 14.17) |
| 3 hours post-dose | 13.1 (11.71 to 14.57) |
| 4 hours post-dose | 12.9 (11.37 to 14.42) |
| 8 hours post-dose | 9.7 (7.75 to 11.62) |
| 12 hours post-dose | 9.0 (6.85 to 11.06) |
| 24 hours post-dose | 5.3 (3.78 to 6.76) |
Change from baseline in heart rate (HR) was calculated based on a linear mixed-effects model with period, sequence, time (categorical), treatment, and time-by-treatment interaction as fixed effects and baseline HR as a covariate.
| bpm | Part B: Omecamtiv Mecarbil 50 mg |
|---|---|
| 0.25 hours post-dose | 1.3 (0.37 to 2.16) |
| 0.5 hours post-dose | 1.2 (0.38 to 2.12) |
| 0.75 hours post-dose | 1.4 (0.51 to 2.37) |
| 1 hour post-dose | 0.2 (-0.86 to 1.18) |
| 1.5 hours post-dose | -0.5 (-1.44 to 0.46) |
| 2 hours post-dose | -0.2 (-1.10 to 0.77) |
| 3 hours post-dose | 1.1 (0.09 to 2.09) |
| 4 hours post-dose | 1.8 (0.77 to 2.84) |
| 8 hours post-dose | 7.8 (6.57 to 9.11) |
| 12 hours post-dose | 8.3 (7.07 to 9.55) |
| 24 hours post-dose | 2.8 (1.66 to 3.95) |
Change from baseline in QTcF was calculated based on a linear mixed-effects model with period, sequence, time (categorical), treatment, and time-by-treatment interaction as fixed effects and baseline QTcF as a covariate.
| ms | Part B: Omecamtiv Mecarbil 50 mg |
|---|---|
| 0.25 hours post-dose | -6.3 (-7.38 to -5.25) |
| 0.5 hours post-dose | -9.1 (-10.30 to -7.98) |
| 0.75 hours post-dose | -8.6 (-9.84 to -7.38) |
| 1 hour post-dose | -8.1 (-9.23 to -6.99) |
| 1.5 hours post-dose | -5.5 (-6.66 to -4.33) |
| 2 hours post-dose | -5.2 (-6.40 to -4.02) |
| 3 hours post-dose | -4.9 (-6.04 to -3.78) |
| 4 hours post-dose | -3.3 (-4.51 to -2.12) |
| 8 hours post-dose | -7.1 (-8.55 to -5.64) |
| 12 hours post-dose | -6.6 (-8.18 to -5.04) |
| 24 hours post-dose | -4.1 (-5.23 to -2.89) |
The PR interval is the time from the onset of the P-wave to the start of the next QRS complex. Change from baseline was calculated based on a linear mixed-effects model with period, sequence, time (categorical), treatment, and time-by-treatment interaction as fixed effects and baseline PR interval as covariate.
| ms | Part B: Omecamtiv Mecarbil 50 mg |
|---|---|
| 0.25 hours post-dose | -0.5 (-1.76 to 0.67) |
| 0.5 hours post-dose | 1.0 (-0.20 to 2.24) |
| 0.75 hours post-dose | 0.4 (-0.87 to 1.76) |
| 1 hour post-dose | 0.4 (-1.02 to 1.75) |
| 1.5 hours post-dose | -1.2 (-2.40 to -0.08) |
| 2 hours post-dose | -0.8 (-2.16 to 0.60) |
| 3 hours post-dose | -2.0 (-3.37 to -0.67) |
| 4 hours post-dose | -3.2 (-4.64 to -1.77) |
| 8 hours post-dose | -7.5 (-9.28 to -5.67) |
| 12 hours post-dose | -7.8 (-9.69 to -5.96) |
| 24 hours post-dose | -2.1 (-3.71 to -0.58) |
The QRS complex is a combination of the Q wave, R wave and S wave on an ECG tracing, and represents ventricular depolarization. Change from baseline was calculated based on a linear mixed-effects model with period, sequence, time (categorical), treatment, and time-by-treatment interaction as fixed effects and baseline QRS as covariate.
| ms | Part B: Omecamtiv Mecarbil 50 mg |
|---|---|
| 0.25 hours post-dose | -0.2 (-0.42 to -0.01) |
| 0.5 hours post-dose | 0.0 (-0.28 to 0.22) |
| 0.75 hours post-dose | -0.2 (-0.37 to 0.02) |
| 1 hour post-dose | 0.0 (-0.28 to 0.33) |
| 1.5 hours post-dose | -0.2 (-0.41 to 0.06) |
| 2 hours post-dose | -0.3 (-0.51 to -0.02) |
| 3 hours post-dose | 0.00 (-0.26 to 0.18) |
| 4 hours post-dose | 0.1 (-0.14 to 0.34) |
| 8 hours post-dose | -0.4 (-0.80 to 0.03) |
| 12 hours post-dose | -0.7 (-1.03 to -0.32) |
| 24 hours post-dose | -0.3 (-0.61 to 0.08) |
The relationship between omecamtiv mecarbil plasma concentration and ΔQTcF was investigated by linear mixed-effects modeling with ΔQTcF as the dependent variable, time-matched concentration of OM as the explanatory variable (0 for placebo), centered baseline QTcF (i.e., baseline QTcF for individual subject minus the population mean baseline QTcF for all subjects in the same period) as an additional covariate, study treatment (OM = 1 or placebo = 0) and time (i.e., post-dose time point) as fixed effects, and a random intercept and slope per subject. From the model, the slope (i.e., the regression parameter for the concentration) was estimated together with the 2-sided 90% CI.
| ms per ng/mL | Part B: Omecamtiv Mecarbil 50 mg |
|---|---|
| Slope of Omecamtiv Mecarbil Plasma Concentration Estimated From Concentration-QTc Analysis in Part B | -0.011 (-0.0154 to -0.0073) |
Change from baseline in heart rate (ΔHR) was calculated based on a linear mixed-effects model with period, sequence, time (categorical), treatment, and time-by-treatment interaction as fixed effects and baseline HR as covariate. Placebo-corrected ΔHR (ΔΔHR) was calculated as the adjusted mean ΔHR after OM dosing minus adjusted mean ΔHR after placebo dosing.
| bpm | Part B: Omecamtiv Mecarbil 50 mg |
|---|---|
| 0.25 hours post-dose | -0.9 (-1.84 to 0.09) |
| 0.5 hours post-dose | -1.3 (-2.27 to -0.42) |
| 0.75 hours post-dose | -0.6 (-1.68 to 0.40) |
| 1 hour post-dose | -2.3 (-3.54 to -1.15) |
| 1.5 hours post-dose | -1.9 (-2.93 to -0.78) |
| 2 hours post-dose | -1.5 (-2.57 to -0.47) |
| 3 hours post-dose | -0.9 (-2.02 to 0.30) |
| 4 hours post-dose | 0.5 (-0.71 to 1.74) |
| 8 hours post-dose | -0.1 (-1.72 to 1.49) |
| 12 hours post-dose | -1.0 (-2.57 to 0.55) |
| 24 hours post-dose | -1.7 (-3.09 to -0.28) |
Change from baseline in PR interval (ΔPR) was calculated based on a linear mixed-effects model with period, sequence, time (categorical), treatment, and time-by-treatment interaction as fixed effects and baseline PR interval as covariate. Placebo-corrected ΔPR (ΔΔPR) was calculated as the adjusted mean ΔPR after OM dosing minus adjusted mean ΔPR after placebo dosing.
| ms | Part B: Omecamtiv Mecarbil 50 mg |
|---|---|
| 0.25 hours post-dose | 0.6 (-1.02 to 2.26) |
| 0.5 hours post-dose | 0.9 (-0.74 to 2.54) |
| 0.75 hours post-dose | -0.3 (-2.07 to 1.50) |
| 1 hour post-dose | 1.0 (-0.89 to 2.87) |
| 1.5 hours post-dose | 0.1 (-1.46 to 1.64) |
| 2 hours post-dose | 1.9 (-0.02 to 3.74) |
| 3 hours post-dose | 0.4 (-1.41 to 2.26) |
| 4 hours post-dose | 0.1 (-1.83 to 2.09) |
| 8 hours post-dose | -1.6 (-4.12 to 0.88) |
| 12 hours post-dose | -1.0 (-3.57 to 1.61) |
| 24 hours post-dose | -0.1 (-2.22 to 2.08) |
Change from baseline in QRS (ΔQRS) was calculated based on a linear mixed-effects model with period, sequence, time (categorical), treatment, and time-by-treatment interaction as fixed effects and baseline QRS as covariate. Placebo-corrected ΔQRS (ΔΔQRS) was calculated as the adjusted mean ΔQRS after OM dosing minus adjusted mean ΔQRS after placebo dosing.
| ms | Part B: Omecamtiv Mecarbil 50 mg |
|---|---|
| 0.25 hours post-dose | -0.1 (-0.34 to 0.21) |
| 0.5 hours post-dose | -0.1 (-0.41 to 0.28) |
| 0.75 hours post-dose | -0.1 (-0.33 to 0.20) |
| 1 hour post-dose | -0.1 (-0.53 to 0.32) |
| 1.5 hours post-dose | 0.0 (-0.33 to 0.32) |
| 2 hours post-dose | 0.1 (-0.28 to 0.39) |
| 3 hours post-dose | 0.1 (-0.18 to 0.41) |
| 4 hours post-dose | 0.1 (-0.22 to 0.44) |
| 8 hours post-dose | 0.3 (-0.32 to 0.85) |
| 12 hours post-dose | 0.4 (-0.07 to 0.91) |
| 24 hours post-dose | -0.1 (-0.60 to 0.36) |
Outliers were predefined according to the following categories: QTcF: Treatment-emergent value of \> 450 and ≤ 480 ms when not present at baseline (new onset) Treatment-emergent value of \> 480 and ≤ 500 ms when not present at baseline (new onset) Treatment-emergent value of \> 500 ms when not present at baseline (new onset) Increase of QTcF from baseline of \> 30 and ≤ 60 ms Increase of QTcF from baseline \> 60 ms Increase of PR from baseline \> 25% resulting in PR \> 200 ms Increase of QRS from baseline \> 25% resulting in QRS \> 120 ms Decrease of HR from baseline \> 25% resulting in HR \< 50 bpm Increase of HR from baseline \> 25% resulting in HR \> 100 bpm
| Participants | Part B: Omecamtiv Mecarbil 50 mg |
|---|---|
| QTcF > 450 and ≤ 480 ms (new onset) | 1 |
| QTcF > 480 and ≤ 500 ms (new onset) | 0 |
| QTcF > 500 ms (new onset) | 0 |
| Increase in ΔQTcF > 30 and ≤ 60 ms | 0 |
| Increase in ΔQTcF > 60 ms | 0 |
| HR < 50 bpm with a decrease in ΔHR > 25% | 0 |
| HR > 100 bpm with an increase in ΔHR > 25% | 0 |
| PR > 200 ms with an increase in ΔPR > 25% | 0 |
| QRS > 120 ms with an increase in ΔQRS > 25% | 0 |
T-wave abnormalities were categorized as follows: Flat T-wave: T amplitude \< 1 mm (either positive or negative) including flat isoelectric line Notched T-wave (+): Presence of notch(es) of at least 0.05 mV amplitude on ascending or descending arm of the positive T-wave Biphasic: T-wave that contains a second component with an opposite phase that is at least 0.1 mV deep (both positive/negative and negative/positive and polyphasic T-waves included) Normal T-wave (-): T amplitude that is negative, without biphasic T-wave or notches Notched T-wave (-): Presence of notch(es) of at least 0.05 mV amplitude on descending or ascending arm of the negative T-wave U waves: Presence of abnormal U-waves
| Participants | Part B: Omecamtiv Mecarbil 50 mg |
|---|---|
| Flat T-wave | 0 |
| Notched T-wave (+) | 0 |
| Biphasic T-wave | 0 |
| Normal T-wave (-) | 0 |
| Notched T-wave (-) | 0 |
| U-Wave presence | 0 |
A TEAE was defined as an adverse event (AE) that started during or after the first dose, or started prior to the first dose and increased in severity after the first dose. A treatment-related TEAE was defined as a TEAE with a relationship of related to the study treatment as determined by the investigator. The Investigator assessed the severity of each AE reported during the study based on the following grading scale: Mild: Aware of sign or symptom, easily tolerated Moderate: Discomfort enough to cause interference with usual activity Severe: Incapacitating, inability to work or do usual activity SAEs were defined as any untoward medical occurrence that met at least 1 of the following serious criteria: * Resulted in Death * Was life-threatening * Required in-patient hospitalization or prolongation of existing hospitalization * Resulted in persistent or significant disability/incapacity * Was a congenital anomaly/birth defect * Other medically important serious event
| Participants | Part A: Omecamtiv Mecarbil 25 mg | Part B: Placebo | Part B: Omecamtiv Mecarbil 50 mg | Part B: Moxifloxacin 400 mg |
|---|---|---|---|---|
| Any TEAE | 20 | 26 | 24 | 29 |
| Serious TEAE | 0 | 0 | 0 | 0 |
| TEAE leading to discontinuation | 0 | 0 | 0 | 0 |
| TEAE leading to death | 0 | 0 | 0 | 0 |
| Mild TEAE | 19 | 25 | 24 | 28 |
| Moderate TEAE | 2 | 1 | 1 | 2 |
| Severe TEAE | 0 | 0 | 0 | 0 |
| Treatment-related TEAE | 2 | 0 | 4 | 2 |
| Treatment-related serious TEAE | 0 | 0 | 0 | 0 |
| Treatment-related TEAE leading to discontinuation | 0 | 0 | 0 | 0 |
| Treatment-related TEAE leading to death | 0 | 0 | 0 | 0 |
| Treatment-related mild TEAE | 2 | 0 | 4 | 2 |
| Treatment-related moderate TEAE | 0 | 0 | 0 | 0 |
| Treatment-related severe TEAE | 0 | 0 | 0 | 0 |
Blood and urine samples were collected for clinical laboratory evaluations (including clinical chemistry, hematology, urinalysis, and serology). Vital signs included blood pressure, pulse rate and body temperature. Standard safety 12-lead ECGs were recorded after the subject had been supine or semi-recumbent and at rest for at least 5 minutes to detect any immediate ECG effects for subject safety. These ECGs were viewed locally. The Investigator determined whether an abnormal value in an individual participant represented a clinically significant change from the participant's baseline values.
| Participants | Part A: Omecamtiv Mecarbil 25 mg | Part B: Placebo | Part B: Omecamtiv Mecarbil 50 mg | Part B: Moxifloxacin 400 mg |
|---|---|---|---|---|
| Clinical Laboratory Evaluations | 0 | 0 | 0 | 0 |
| Vital Signs | 0 | 0 | 0 | 0 |
| 12-lead Electrocardiogram | 0 | 0 | 0 | 0 |
Change from baseline in QTcF was calculated based on a linear mixed-effects model with period, sequence, time (categorical), treatment, and time-by-treatment interaction as fixed effects and baseline QTcF as a covariate.
| ms | Part B: Omecamtiv Mecarbil 50 mg | Part B: Moxifloxacin 400 mg | Part B: Placebo |
|---|---|---|---|
| 0.25 hours post-dose | -6.3 (-7.38 to -5.25) | -1.6 (-2.61 to -0.49) | -3.8 (-4.82 to -2.70) |
| 0.5 hours post-dose | -9.1 (-10.30 to -7.98) | 4.4 (3.21 to 5.53) | -4.2 (-5.37 to -3.05) |
| 0.75 hours post-dose | -8.6 (-9.84 to -7.38) | 7.2 (6.01 to 8.47) | -2.8 (-4.08 to -1.62) |
| 1 hour post-dose | -8.1 (-9.23 to -6.99) | 8.8 (7.63 to 9.88) | -1.4 (-2.52 to -0.28) |
| 1.5 hours post-dose | -5.5 (-6.66 to -4.33) | 10.1 (8.89 to 11.23) | -1.0 (-2.20 to 0.13) |
| 2 hours post-dose | -5.2 (-6.40 to -4.02) | 10.1 (8.95 to 11.33) | -2.5 (-3.70 to -1.33) |
| 3 hours post-dose | -4.9 (-6.04 to -3.78) | 9.8 (8.63 to 10.89) | -3.4 (-4.51 to -2.25) |
| 4 hours post-dose | -3.3 (-4.51 to -2.12) | 10.4 (9.21 to 11.59) | -2.5 (-3.68 to -1.30) |
| 8 hours post-dose | -7.1 (-8.55 to -5.64) | 4.8 (3.30 to 6.22) | -4.9 (-6.38 to -3.47) |
| 12 hours post-dose | -6.6 (-8.18 to -5.04) | 4.2 (2.66 to 5.80) | -4.7 (-6.30 to -3.16) |
| 24 hours post-dose | -4.1 (-5.23 to -2.89) | 2.4 (1.23 to 3.57) | -2.9 (-4.04 to -1.70) |
Change from baseline in heart rate (HR) was calculated based on a linear mixed-effects model with period, sequence, time (categorical), treatment, and time-by-treatment interaction as fixed effects and baseline HR as a covariate.
| bpm | Part B: Omecamtiv Mecarbil 50 mg | Part B: Moxifloxacin 400 mg | Part B: Placebo |
|---|---|---|---|
| 0.25 hours post-dose | 1.3 (0.37 to 2.16) | 2.1 (1.22 to 3.01) | 2.1 (1.25 to 3.04) |
| 0.5 hours post-dose | 1.2 (0.38 to 2.12) | 4.0 (3.14 to 4.88) | 2.6 (1.72 to 3.47) |
| 0.75 hours post-dose | 1.4 (0.51 to 2.37) | 5.3 (4.33 to 6.20) | 2.1 (1.15 to 3.01) |
| 1 hour post-dose | 0.2 (-0.86 to 1.18) | 5.4 (4.39 to 6.43) | 2.5 (1.49 to 3.53) |
| 1.5 hours post-dose | -0.5 (-1.44 to 0.46) | 2.0 (1.06 to 2.97) | 1.4 (0.41 to 2.32) |
| 2 hours post-dose | -0.2 (-1.10 to 0.77) | 2.0 (1.05 to 2.93) | 1.4 (0.41 to 2.29) |
| 3 hours post-dose | 1.1 (0.09 to 2.09) | 3.0 (1.97 to 3.97) | 2.0 (0.96 to 2.95) |
| 4 hours post-dose | 1.8 (0.77 to 2.84) | 2.9 (1.88 to 3.95) | 1.3 (0.25 to 2.32) |
| 8 hours post-dose | 7.8 (6.57 to 9.11) | 9.1 (7.83 to 10.38) | 8.0 (6.69 to 9.22) |
| 12 hours post-dose | 8.3 (7.07 to 9.55) | 9.6 (8.37 to 10.85) | 9.3 (8.08 to 10.56) |
| 24 hours post-dose | 2.8 (1.66 to 3.95) | 3.4 (2.30 to 4.59) | 4.5 (3.34 to 5.63) |
The PR interval is the time from the onset of the P-wave to the start of the next QRS complex. Change from baseline was calculated based on a linear mixed-effects model with period, sequence, time (categorical), treatment, and time-by-treatment interaction as fixed effects and baseline PR interval as covariate.
| ms | Part B: Omecamtiv Mecarbil 50 mg | Part B: Moxifloxacin 400 mg | Part B: Placebo |
|---|---|---|---|
| 0.25 hours post-dose | -0.5 (-1.76 to 0.67) | -1.6 (-2.85 to -0.42) | -1.2 (-2.38 to 0.06) |
| 0.5 hours post-dose | 1.0 (-0.20 to 2.24) | -0.6 (-1.78 to 0.66) | 0.1 (-1.10 to 1.34) |
| 0.75 hours post-dose | 0.4 (-0.87 to 1.76) | -1.1 (-2.40 to 0.24) | 0.7 (-0.58 to 2.05) |
| 1 hour post-dose | 0.4 (-1.02 to 1.75) | -1.5 (-2.83 to -0.07) | -0.6 (-2.00 to 0.76) |
| 1.5 hours post-dose | -1.2 (-2.40 to -0.08) | -2.1 (-3.24 to -0.91) | -1.3 (-2.48 to -0.17) |
| 2 hours post-dose | -0.8 (-2.16 to 0.60) | -1.6 (-2.99 to -0.24) | -2.6 (-4.02 to -1.26) |
| 3 hours post-dose | -2.0 (-3.37 to -0.67) | -3.3 (-4.64 to -1.94) | -2.5 (-3.80 to -1.10) |
| 4 hours post-dose | -3.2 (-4.64 to -1.77) | -4.5 (-5.90 to -3.04) | -3.3 (-4.77 to -1.90) |
| 8 hours post-dose | -7.5 (-9.28 to -5.67) | -7.7 (-9.55 to -5.93) | -5.8 (-7.65 to -4.04) |
| 12 hours post-dose | -7.8 (-9.69 to -5.96) | -7.5 (-9.37 to -5.63) | -6.8 (-8.72 to -4.98) |
| 24 hours post-dose | -2.1 (-3.71 to -0.58) | -2.6 (-4.14 to -1.01) | -2.1 (-3.64 to -0.51) |
The QRS complex is a combination of the Q wave, R wave and S wave on an ECG tracing, and represents ventricular depolarization. Change from baseline was calculated based on a linear mixed-effects model with period, sequence, time (categorical), treatment, and time-by-treatment interaction as fixed effects and baseline QRS as covariate.
| ms | Part B: Omecamtiv Mecarbil 50 mg | Part B: Moxifloxacin 400 mg | Part B: Placebo |
|---|---|---|---|
| 0.25 hours post-dose | -0.2 (-0.42 to -0.01) | -0.2 (-0.43 to -0.02) | -0.2 (-0.36 to 0.05) |
| 0.5 hours post-dose | 0.0 (-0.28 to 0.22) | -0.1 (-0.36 to 0.15) | 0.0 (-0.22 to 0.29) |
| 0.75 hours post-dose | -0.2 (-0.37 to 0.02) | 0.0 (-0.18 to 0.21) | -0.1 (-0.31 to 0.08) |
| 1 hour post-dose | 0.0 (-0.28 to 0.33) | 0.1 (-0.25 to 0.36) | 0.1 (-0.18 to 0.44) |
| 1.5 hours post-dose | -0.2 (-0.41 to 0.06) | 0.0 (-0.27 to 0.21) | -0.2 (-0.41 to 0.07) |
| 2 hours post-dose | -0.3 (-0.51 to -0.02) | 0.1 (-0.16 to 0.33) | -0.3 (-0.56 to -0.07) |
| 3 hours post-dose | 0.00 (-0.26 to 0.18) | 0.1 (-0.15 to 0.29) | -0.2 (-0.37 to 0.07) |
| 4 hours post-dose | 0.1 (-0.14 to 0.34) | 0.2 (-0.04 to 0.44) | 0.0 (-0.25 to 0.23) |
| 8 hours post-dose | -0.4 (-0.80 to 0.03) | -0.3 (-0.76 to 0.08) | -0.6 (-1.07 to -0.23) |
| 12 hours post-dose | -0.7 (-1.03 to -0.32) | -0.7 (-1.10 to -0.40) | -1.1 (-1.45 to -0.74) |
| 24 hours post-dose | -0.3 (-0.61 to 0.08) | 0.0 (-0.35 to 0.33) | -0.1 (-0.49 to 0.20) |
Collected over From first dose of study drug to 6 days post-dose in each treatment period.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Omecamtiv Mecarbil 25 mg | 0/70 (0%) | 0/70 (0%) | 14/70 (20%) |
| Part B: Placebo | 0/60 (0%) | 0/60 (0%) | 16/60 (26.7%) |
| Part B: Omecamtiv Mecarbil 50 mg | 0/60 (0%) | 0/60 (0%) | 13/60 (21.7%) |
| Part B: Moxifloxacin 400 mg | 0/60 (0%) | 0/60 (0%) | 18/60 (30%) |
| Overall | 0/70 (0%) | 0/70 (0%) | 39/70 (55.7%) |
| Event | Part A: Omecamtiv Mecarbil 25 mg | Part B: Placebo | Part B: Omecamtiv Mecarbil 50 mg | Part B: Moxifloxacin 400 mg | Overall |
|---|---|---|---|---|---|
| Post procedural erythemaInjury, poisoning and procedural complications | 2/70 | 6/60 | 5/60 | 5/60 | 15/70 |
| Post procedural complicationInjury, poisoning and procedural complications | 4/70 | 2/60 | 3/60 | 1/60 | 10/70 |
| HeadacheNervous system disorders | 1/70 | 3/60 | 3/60 | 2/60 | 9/70 |
| NauseaGastrointestinal disorders | 1/70 | 4/60 | 1/60 | 3/60 | 7/70 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 3/70 | 0/60 | 3/60 | 1/60 | 7/70 |
| InsomniaPsychiatric disorders | 1/70 | 2/60 | 2/60 | 1/60 | 6/70 |
| DizzinessNervous system disorders | 1/70 | 2/60 | 0/60 | 2/60 | 5/70 |
| NasopharyngitisInfections and infestations | 1/70 | 1/60 | 2/60 | 0/60 | 4/70 |
| Procedural painInjury, poisoning and procedural complications | 0/70 | 0/60 | 1/60 | 3/60 | 4/70 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 1/70 | 1/60 | 0/60 | 2/60 | 4/70 |
Participants randomized in Part B of the study
| Age, Continuous(years) | Part B |
|---|---|
| Mean | 32.7 ± 8.88 |
| Sex: Female, Male(Participants) | Part B |
|---|---|
| Female | 26 |
| Male | 34 |
| Ethnicity (NIH/OMB)(Participants) | Part B |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 60 |
| Unknown or Not Reported | 0 |
| Race/Ethnicity, Customized(Participants) | Part B |
|---|---|
| White | 49 |
| Black or African American | 6 |
| Asian | 4 |
| Native Hawaiian or Other Pacific Islander | 0 |
| American Indian or Alaska Native | 0 |
| Multiple | 1 |
| QT Interval Corrected for Heart Rate Based on the Fridericia Method (QTcF)(ms) | Part B |
|---|---|
| Prior to OM dose | 402.9 ± 18.27 |
| Prior to moxifloxacin dose | 402.4 ± 18.38 |
| Prior to placebo dose | 404.1 ± 19.06 |
| PR Interval(ms) | Part B |
|---|---|
| Prior to OM dose | 151.4 ± 22.48 |
| Prior to moxifloxacin dose | 150.7 ± 22.73 |
| Prior to placebo dose | 151.2 ± 24.20 |
| QRS(ms) | Part B |
|---|---|
| Prior to OM dose | 105.6 ± 5.74 |
| Prior to moxifloxacin dose | 105.8 ± 5.36 |
| Prior to placebo dose | 105.8 ± 5.52 |
| Heart Rate(beats/minute) | Part B |
|---|---|
| Prior to OM dose | 59.2 ± 7.87 |
| Prior to moxifloxacin dose | 59.5 ± 7.36 |
| Prior to placebo dose | 58.6 ± 8.03 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.
Data sharing details ↗ · www.amgen.com
Ran from Nov 2019 to primary completion in Mar 2020, 3 months.
Results were first posted in Jul 2021, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Omecamtiv mecarbil